Analysts Offer Predictions for CTXR FY2026 Earnings

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Citius Pharmaceuticals in a research note issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($1.87) per share for the year. HC Wainwright currently has a “Buy” rating and a $4.00 price target on the stock.

A number of other equities research analysts have also recently commented on the company. D. Boral Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Citius Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $5.00.

Citius Pharmaceuticals Stock Up 5.2%

Shares of Citius Pharmaceuticals stock opened at $0.55 on Wednesday. Citius Pharmaceuticals has a 12 month low of $0.48 and a 12 month high of $2.48. The business has a fifty day simple moving average of $0.77 and a 200 day simple moving average of $0.90. The stock has a market cap of $15.21 million, a PE ratio of -0.23 and a beta of 1.05.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). The company had revenue of $1.67 million during the quarter, compared to analyst estimates of $10.23 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTXR. XTX Topco Ltd bought a new position in Citius Pharmaceuticals during the second quarter worth about $32,000. NewEdge Advisors LLC bought a new position in Citius Pharmaceuticals during the second quarter worth about $40,000. Asset Advisory Group Inc. bought a new position in Citius Pharmaceuticals during the fourth quarter worth about $46,000. Finally, Heights Capital Management Inc. bought a new position in Citius Pharmaceuticals during the fourth quarter worth about $622,000. 16.88% of the stock is currently owned by institutional investors.

Key Citius Pharmaceuticals News

Here are the key news stories impacting Citius Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Citius Pharmaceuticals and maintained a $4.00 price target, signaling strong expected upside for the stock. Benzinga
• Neutral Sentiment: The firm also published updated earnings estimates for fiscal 2026 and 2027, forecasting continued losses but without any change to its positive rating outlook. American Banking News
• Neutral Sentiment: Recent reports included detailed quarterly EPS forecasts through 2027, reinforcing that investors are focused on future pipeline and profitability expectations rather than near-term earnings. American Banking News

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.